Clinical trials
CAR T Cell clinical trials
Below are recruiting car t cell clinical trials, each written for real people, not researchers. We’re tracking 675 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT05464719RecruitingPhase 2
Loncastuximab for lymphoma patients in partial remission after CAR T
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
Houston, TexasAges 18 years+ - NCT06010875RecruitingPhase 1
CD70-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new treatment using your own immune cells (CAR-T cells) designed to attack cancer cells that have a protein called CD70. It is for people with advanced solid tumors that have not responded to standard treatments.
Nanchang, JiangxiAges 18 years+ - NCT05410717RecruitingPhase 1
CAR-NK cell therapy for certain solid tumors
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
Guangzhou, GuangdongAges 18–75 - NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT06703892RecruitingPhase 1
CAR T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
TaipeiAges 18–70 - NCT06706102RecruitingPhase 4
Study of Tiny Blood Particles During CAR-T Therapy
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
Saint-EtienneAges 18 years+ - NCT07181720RecruitingPhase 1
CD70-targeted CAR-T therapy for advanced solid tumors
This trial tests a new treatment called CAR-T that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments.
Hefei, AnhuiAges 18 years+ - NCT06479356RecruitingPhase 2
CAR T-cell therapy for relapsed large B-cell lymphoma
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06836505RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed neuroblastoma and related tumors
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
Guangzhou, GuangdongAges 1–50 - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+ - NCT06904131Recruiting
CAR-T cell therapy for advanced gynecological cancers
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT07244406RecruitingPhase 2
CAR-T cell therapy for relapsed B-ALL
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
BeijingAges 3–25 - NCT07390071Recruiting
Remote rehab program for CAR-T cell therapy patients
This trial tests a home-based rehabilitation program using phone or video sessions to help people with lymphoma or myeloma recover better after CAR-T cell therapy. It aims to improve physical function and quality of life during treatment.
Salt Lake City, UtahAges 21 years+ - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT07193667Recruiting
CAR-T therapy for autoimmune diseases
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Shenyang, LiaoningAges 18–65 - NCT04532281RecruitingEarly Phase 1
CD19 CAR-T therapy for relapsed or resistant blood cancers
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
Hangzhou, ZhejiangAges Any age - NCT05326243RecruitingPhase 1/Phase 2
CAR-T therapy for hard-to-treat B-cell lymphoma
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
Taipei, TaiwanAges 14 years+ - NCT04648046RecruitingPhase 1/Phase 2
CAR-T cell treatment for HIV infection
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
Sacramento, CaliforniaAges 18–65 - NCT06593145RecruitingPhase 1
CAR-T therapy for relapsed CD19+ B-cell cancers
This trial tests a new type of CAR-T cell therapy for people with certain B-cell cancers (leukemia or lymphoma) that have not responded to standard treatments. It aims to see if these specially engineered immune cells can attack and destroy the cancer.
Warsaw, Ul. Banacha 1aAges 18–65 - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car t cell?
- Yes. Clin2 currently lists 675 recruiting car t cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car t cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car t cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.